Search Results - "Kashlakova, Anastasiya"

PB1866: IS ALLO‐HSCT IN CR1 NECESSARY FOR AML PATIENTS WITH MRD NEGATIVITY ACHIEVED AFTER THE FIRST INDUCTION COURSE? RUSSIAN PROSPECTIVE MULTICENTER RANDOMIZED TRIAL IN AML PATIENTS UNDER THE AGE OF 60 by Parovichnikova, Elena, Lukianova, Irina, Galtzeva, Irina, Kashlakova, Anastasiya, Fidarova, Zalina, Aleshina, Olga, Kuzmina, Larisa, Troitskaya, Vera, Drokov, Mikhail, Sokolov, Andrey, Bondarenko, Sergej, Samoilova, Olga, Grishunina, Mariya, Konstantinova, Tatiana, Sveshnikova, Yuliya, Minaeva, Natalia, Zinina, Elena, Lapin, Valerij, Kaplanov, Kamil, Gritsaev, Sergej, Gribanova, Elena, Dvirnyk, Valentina, Obukhova, Tatiana, Sudarikov, Andrej, Chabaeva, Yuliya

Get full text

POSTER: AML-333 Microarray Molecular Karyotype vs Standard Cytogenetic Analysis in Patients With Acute Myeloid Leukemia (AML) With inv(16) by Bessmertnyy, Dmitry, Risinskaya, Natalya, Kashlakova, Anastasiya, Lukianova, Irina, Fidarova, Zalina, Kislitsyna, Mariya, Obukhova, Tatyana, Julhakyan, Hunan, Sudarikov, Andrey

Get full text

AML-333 Microarray Molecular Karyotype vs Standard Cytogenetic Analysis in Patients With Acute Myeloid Leukemia (AML) With inv(16) by Bessmertnyy, Dmitry, Risinskaya, Natalya, Kashlakova, Anastasiya, Lukianova, Irina, Fidarova, Zalina, Kislitsyna, Mariya, Obukhova, Tatyana, Julhakyan, Hunan, Sudarikov, Andrey

“…The landscape of copy number alterations (CNA) and copy-neutral loss of heterozygosity (cnLOH) is important for understanding the nature of myeloid neoplasms…”
Get full text